247092-10-0

Basic information

• Product Name: METHYL 2-CHLORO-5-HYDROXYBENZOATE
• Synonyms: METHYL 2-CHLORO-5-HYDROXYBENZOATE;2-Chloro-5-hydroxybenzoic acid Methyl ester
• CAS NO: 247092-10-0
• Molecular Formula: C₈H₇ClO₃
• Molecular Weight: 186.6
• Mol File: 247092-10-0.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 320.1°C at 760 mmHg
• Flash Point: 147.4°C
• Appearance: /
• Density: 1.354g/cm³
• Vapor Pressure: 0.000173mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 8.70±0.18(Predicted)
• CAS DataBase Reference: METHYL 2-CHLORO-5-HYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-CHLORO-5-HYDROXYBENZOATE(247092-10-0)
• EPA Substance Registry System: METHYL 2-CHLORO-5-HYDROXYBENZOATE(247092-10-0)

Safety Data

• Hazardous Substances Data: 247092-10-0(Hazardous Substances Data)

Usage

General Description

Methyl 2-chloro-5-hydroxybenzoate, also known as methyl 2-chloro-5-hydroxybenzoate, is a chemical compound with the molecular formula C8H7ClO3. It is a derivative of benzoic acid and is often used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. METHYL 2-CHLORO-5-HYDROXYBENZOATE is known for its antimicrobial and antioxidant properties, and its ability to inhibit the growth of certain bacteria and fungi. It is also used as a preservative in cosmetic and personal care products. Methyl 2-chloro-5-hydroxybenzoate is considered to be a relatively safe and stable compound when used in accordance with recommended guidelines.

InChI:InChI=1/C8H7ClO3/c1-12-8(11)6-4-5(10)2-3-7(6)9/h2-4,10H,1H3

Upstream product

• 19438-10-9 methyl 3-hydroxybenzoate 
• 89-54-3 2-chloro-5-aminobenzoic acid 
• 67-56-1 methanol 
• 56961-30-9 2-chloro-5-hydroxybenzoic acid 

Downstream Products

• 1001026-31-8 ethyl 6-{4-[allyl(benzylsulfonyl)carbamoyl]piperidin-1-yl}-5-cyano-2-(2,2-difluoroethoxy)nicotinate 
• 1422205-92-2 methyl 2-chloro-5-(4,4,4-trifluorobutoxy)benzoate 
• 1422205-91-1 methyl 2-chloro-5-(2,2-difluoroethoxy)benzoate 
• 1403782-72-8 2-chloro-5-(4,4,4-trifluorobutoxy)benzoic acid 
• 1422205-90-0 2-chloro-5-(2,2-difluoroethoxy)benzoic acid 
• 1394349-19-9 2-chloro-5-(2-methoxy-pyrimidin-4-ylsulfanyl)-benzoic acid 
• 1394349-16-6 2-chloro-5-[2-(2-trimethylsilanyl-ethoxy)-pyrimidin-4-ylsulfanyl]-benzoic acid 

Relevant articles and documents

NOVEL INHIBITORS OF MAP4K1

The invention relates to novel inhibitors of MAP4K1 (HPK1) useful for the treatment of diseases or disorders characterised by dysregulation of the signal transduction pathways associated with MAPK activation, including hyperproliferative diseases, diseases of immune system dysfunction, inflammatory disorders, neurological diseases, and cardiovascular diseases. The invention further relates to pharmaceutical compositions comprising the same and methods of treatment of said diseases and disorders. The inhibitors are of formula (I) wherein the definitions for A, D, E, F, R5, R6, R7, Z, ring Q, n, x and y are as given in the application.

Rapid Access to Orthogonally Functionalized Naphthalenes: Application to the Total Synthesis of the Anticancer Agent Chartarin

We report the synthesis of orthogonally functionalized naphthalenes from simple, commercially available indanones in four steps. The developed method proceeds through a two-step process that features a thermally induced fragmentation of a cyclopropane indanone with simultaneous 1,2-chloride shift. Migration of the chloride substituent occurs in a regioselective manner to preferentially afford the para-chloronaphthol substitution pattern. The obtained naphthols are versatile building blocks that can be selectively modified and used for the efficient construction of biologically active molecules. This has enabled the total synthesis of the potent anticancer natural product chartarin through a highly convergent retrosynthetic bond disconnection.

Structure-based design of a potent, selective, and brain penetrating PDE2 inhibitor with demonstrated target engagement

Structure-guided design led to the identification of the novel, potent, and selective phosphodiesterase 2 (PDE2) inhibitor 12. Compound 12 demonstrated a >210-fold selectivity versus PDE10 and PDE11 and was inactive against all other PDE family members up